Day: June 29, 2023

The 2023 class includes academically elite students attending Brown University, Sofia University and Technical University in Sofia. BURLINGTON, Mass., June 29, 2023 (GLOBE NEWSWIRE) — Progress (Nasdaq: PRGS), the trusted provider of application development and infrastructure software, today announced the 2023 recipients of its Women in STEM Scholarship Series in the US and Bulgaria. Established in 2019 and available to those who identify as women, the scholarship series aims to open opportunities to students looking to study computer science, software engineering, IT and/or computer information systems. “We have the honor every year of meeting incredible young women who are passionate about computer science and have a desire to use that passion to make a positive impact on the world,” said Yogesh Gupta, CEO, Progress. “It is inspiring...

Reference is made to the stock exchange announcement published on 15 June 2023 by Ensurge Micropower ASA (“Ensurge“ or the “Company”) regarding a proposed subsequent offering of new shares in the Company raising a maximum amount of NOK 20 million (the “Subsequent Offering”). Further reference is made to the announcement made by the Company on 20 June 2023, such announcement containing the Notice of the Extraordinary General Meeting scheduled for 11 July 2023 (“EGM”). The EGM will consider, among other things, the proposed Subsequent Offering.   The subscription period for the Subsequent Offering may not commence before a prospectus has been approved by the Norwegian Financial Supervisory Authority (“FSA”). Due to shortage of staff at the FSA over the course of the summer, the prospectus control process will be delayed compared with the...

— Represents the final step before submission of Investigational New Drug (IND) application to FDA, expected in the second half of 2023 — PALO ALTO, Calif. and MIAMI, June 29, 2023 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (“CNS”) disorders, today announced it has successfully completed manufacturing of GMP-compliant Phase 1 clinical supplies of the active pharmaceutical ingredient (“API”) of its lead product candidate PAS-004, a next-generation macrocyclic MEK Inhibitor. GMP-compliant manufacturing of API was the final step needed to support the Investigational New Drug (“IND”) application that the Company expects to file with the U.S. Food...